TG Therapeutics Reports Strong 2025 Results, Raises 2026 Revenue Guidance to $875-$900M, and Authorizes New $100M Buyback

summarizeSummary

TG Therapeutics announced strong Q4 and full-year 2025 financial results, raised its 2026 revenue guidance, and authorized a new $100 million share repurchase program, highlighting significant growth for BRIUMVI and pipeline progress.

check_boxKey Events

• Strong 2025 Financial Performance

  Reported Q4 2025 total revenue of $192.6 million and full-year 2025 total revenue of $616.3 million. BRIUMVI U.S. net revenue reached $182.7 million in Q4 2025, representing approximately 20% quarterly growth, and $594.1 million for the full year, a 92% year-over-year increase.

• Raised 2026 Revenue Guidance

  Set full-year 2026 target total global revenue at approximately $875-$900 million, including BRIUMVI U.S. net product revenue of approximately $825-$850 million. This follows previous bullish guidance and confirms strong growth expectations.

• New Share Repurchase Program Authorized

  Completed a prior $100 million share repurchase program in Q3 2025, acquiring approximately 3.5 million shares at an average price of $28.55. The board has now authorized a new program to acquire up to an additional $100 million of common stock.

• Pipeline Advancement and Milestones

  Achieved approximately 75% patient enrollment in the Phase 3 subcutaneous ublituximab program and completed enrollment for the ENHANCE trial's consolidated dosing regimen. Anticipated 2026 milestones include pivotal topline data for ENHANCE (mid-year) and subcutaneous BRIUMVI (year-end 2026/1Q 2027), along with preliminary Phase 1 azer-cel data in Progressive MS (2H 2026).

auto_awesomeAnalysis

TG Therapeutics delivered robust financial results for Q4 and full-year 2025, significantly driven by its key drug BRIUMVI, which saw 92% year-over-year U.S. net revenue growth. The company has raised its 2026 total global revenue guidance to $875-$900 million, indicating continued strong growth expectations. Additionally, the board authorized a new $100 million share repurchase program, signaling confidence in the company's valuation and financial health. Positive clinical updates for BRIUMVI and azer-cel further support the company's long-term growth trajectory.